A glycopeptide antitumor antibiotic
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Bleomycin (sulfate)

Item No. 13877

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
bleomycin sulfate (salt)
CAS Number
9041-93-4
Synonyms
  • Blenoxane
Molecular Formula
C55H84N17O21S3 • XHSO4 (for A2)
Formula Weight
1415.6
Purity
≥95% (mixture of A2 and B2)
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 2 mg/mlDMSO: 13 mg/mlPBS (pH 7.2): 10 mg/ml
λmax
294 nm
SMILES
NC(C[C@H](NC[C@H](N)C(N)=O)C1=NC(N)=C(C)C(C(N[C@H](C(N[C@@H]([C@H]([C@H](C)C(N[C@@H]([C@@H](C)O)C(NCCC2=NC(C3=NC(C(NCCC[S+](C)C)=O)=CS3)=CS2)=O)=O)O)C)=O)C(O[C@@H]4O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]4O[C@@H]5[C@@H](O)[C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O5)C6=CNC=N6)=O)=N1)=O.O=S(O)([O-])=O
InChi Code
InChI=1S/C55H83N17O21S3.H2O4S/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6;1-5(2,3)4/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88);(H2,1,2,3,4)/t21-,22+,23+,24-,25-,29-,30+,34-,35-,36-,37+,38+,39-,40-,41?,42-,43-,53+,54-;/m0./s1
InChi Key
WUIABRMSWOKTOF-VXXHAVRASA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $39

    Add

    5 mg

    $97

    Add

    10 mg

    $154

    Add

    50 mg

    $578

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Bleomycin is a glycopeptide antitumor antibiotic produced by the bacterium S. verticillus. Its mechanism of action causes single- and double-strand DNA breaks in tumor cells, which interrupts the cell cycle.1 Bleomycin is thought to achieve this by chelating metal ions, producing a pseudoenzyme that reacts with oxygen to produce superoxide and hydroxide free radicals that cleave DNA.1 Bleomycin has been used for the treatment of Hodgkin’s lymphoma in combination with doxorubicin, squamous cell carcinomas, testicular cancer, as well as in animal models of pulmonary fibrosis.2,3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Hecht, S.M. Bleomycin: New perspectives on the mechanism of action. J. Nat. Prod. 63(1), 158-168 (2000).

    2. Martinelli, G., Cocorocchio, E., Saletti, P.C., et al. Efficacy of vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy with involved field radiotherapy in early stage (I-IIA) Hodgkin disease patients. Leuk. Lymphoma 44(11), 1919-1923 (2003).

    Product Citations

    Pemmari, A., Leppänen, T., Paukkeri, E.-L., et al. Attenuating effects of nortrachelogenin on IL-4 and IL-13 induced alternative macrophage activation and on bleomycin-induced dermal dibrosis. J. Agric. Food Chem. 66(51), 13405-13413 (2018).